Allurion Technologies Holdings Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allurion Technologies reports Q3 revenue decline, eyes FDA approval

Allurion Technologies Holdings Inc faced challenges in Q3 due to the suspension of the Allurion Balloon in France and macro headwinds, leading to a decrease in revenue. However, the company highlighted strengths in the Middle East and Latin America, with plans to double revenues by year-end and pursue FDA approval for the Allurion Balloon.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis.

Allurion Technologies, Inc. Announces Reverse Stock Split

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the “Minimum Market Capitalization Standard”.

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company's AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the.

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Allurion Technologies Inc. (NYSE:ALUR ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executive Officer Brian Conyer – Vice President-Digital Health Adrian Wild – Senior Vice President-International Commercial Chris Geberth – Chief Financial Officer Conference Call Participants Josh Jennings – TD Cowen Matt Taylor – Jefferies Operator Thank you for standing by. My name is John, and I'll be your conference operator today.

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% v.

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion's largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual.

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (int.

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.

ALUR Stock Declines Despite Submitting PMA for Allurion Balloon

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year. "These submissions are a critical milestone for Allurion, and I commend ou.

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Gevo

KULR Technology Group

Lucid Diagnostics

Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body composition. The study evaluated weight loss and body composition changes for 167 patients with an average body mass index (BMI) of 31.3. After four months of balloon therapy, patients achieved an average weight reduction of 15.7%. Patients con.

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduc.

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE's continued listing standards because the average market capitalization of the Company was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and the Company's last r.

Allurion Receives Continued Listing Standards Notice from NYSE

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Averag.

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. “I believe having Keith as a sou.

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program's ongoing virtual guidance and support. In the study, 486.

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Technologies Inc. (NYSE:ALUR ) Q2 2024 Earnings Call Transcript August 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Shantanu Gaur - Founder and CEO Chris Geberth - CFO Conference Call Participants Keay Nakae - Chardan Matt Taylor - Jefferies Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. Recent Company Highlights Second quarter revenue of $11.8 million, a sequential increase of $2.4 million or 25% from the first quarter of 2024 Second quarter loss from operations reduced by 30% compared to the year-ago period and by 44% when o.

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase 14,406,508 Shares (the “Warrants” and, together with the Shares, the “Securities”) at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before de.

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.

Allurion Announces Launch of Offering of Common Stock and Warrants

Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name.

Why Is Allurion (ALUR) Stock Up 140% Today?

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite. In the st.

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.

Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy

The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News for Allurion Technologies Holdings Inc Stock (ALUR)